Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis

Figures & data

Figure 1 Flowchart of the study selection process.

Table 1 FoxM1 clinicopathological features for HCC

Heterogeneity
Clinicopathological features	No. of studies	No. of patients	Pooled OR (95% CI)	PHet	I^Citation2 (%)	P-value	Model used
Expression	7	1,659	6.54 (3.84–11.14)	0.000	78.4	<0.001	Random
Gender	11	1,491	0.89 (0.67–1.17)	0.536	0.0	0.391	Fixed
HBsAg	8	1,042	1.33 (0.93–1.91)	0.173	32.0	0.871	Fixed
Liver cirrhosis	8	1,300	1.05 (0.81–1.37)	0.054	49.3	0.693	Fixed
AFP	10	1,258	1.26 (1.00–1.59)	0.157	31.4	0.054	Fixed
Tumor size	6	783	0.47 (0.35–0.64)	0.164	36.4	<0.001	Fixed
Tumor number	4	502	0.90 (0.42–1.93)	0.079	55.9	0.793	Random
Vascular invasion	11	1,491	2.61 (1.93–3.53)	0.091	38.7	<0.001	Fixed
Differentiation	12	1,516	2.87 (2.14–3.84)	0.106	35.5	<0.001	Random
TNM stage	10	1,453	0.34 (0.26–0.44)	0.322	13.1	<0.001	Fixed

Abbreviations: HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; OR, odds ratio; AFP, alpha fetoprotein.

Figure 2 Forest plot and funnel plots of the studies evaluating the relationship between FoxM1 expression and clinicopathological features.

Notes: (A) expression; (B) gender. Weights are from random-effects analysis.

Figure 3 Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features.

Notes: (A) HBsAg; (B) AFP.

Figure 4 Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features.

Notes: (A) Liver cirrhosis; (B) tumor size.

Figure 5 Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features.

Notes: (A) Vascular invasion; (B) tumor number. Weights are from random-effects analysis.

Figure 6 Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features.

Notes: (A) Differentiation; (B) TNM stage.

Figure 7 Forest plot and funnel plots of studies evaluating the relationship between FOXM1 expression and prognosis.

Notes: (A) 3-year overall survival; (B) 5-year overall survival.

Figure 8 Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and prognosis.

Notes: (A) 3-year recurrence-free survival; (B) 5-year recurrence-free survival; (C) disease-free survival.

Table 2 Characteristics of studies included in the meta-analysis

Author	Year	Jountry	Kind	No of patients	Experimental method	Antibody	Antibody concentration	Cut-off value	Expression:cancer (+/−) control (+/−)	Gender male (+/−) female (+/−)	HBsAg i yes (+/−) no (+/−)	Liver cirrhosis yes (+/−) no (+/−)	AFP positive (+/−) negative (+/−)	Tumor number single (+/−) multiple (+/−)	Tumor size ≤5 cm (+/−) >5 (+/−)	Vascular invasion yes (+/−) no (+/−)	Differentiation low (+/−) : high and moderate (+/−)	UICC stage I, II (+/−) III, IV (+/−)	Survival information	Quality score (NOS)
Lin et al^Citation12	2010	China	HCC	91	IHC	Santa Cruz	1:100	>25%	73/18 6/85	57/16 16/2	NA	NA	NA	NA	50/8 23/10	31/6 42/12	22/2 51/16	38/12 35/6	NA	7
LiJie et al^Citation17	2010	China	HCC	60	IHC	Abcam	1:50	>10%	39/21 19/41	NA NA	NA	NA	18/9 17/16	18/16 16/10	23/18 15/4	NA	21/6 17/16	17/15 25/3	NA	6
Sun et al^Citation14	2011	China	HCC	150	IHC	Santa Cruz	1:50	>10%	89/62 36/115	79/51 10/10	85/57 4/4	77/60 12/1	54/28 31/33	NA	NA	33/7 56/54	24/8 65/53	43/51 46/10	OS RFS	8
Sun et al^Citation18	2011	China	HCC	99	IHC	Santa Cruz	1:50	>10%	42/57 16/83	39/46 3/11	40/55 2/2	39/57 3/0	18/26 22/31	NA	NA	38/56 4/1	6/3 36/54	34/54 8/3	OS RFS	8
Mo^Citation19	2012	China	HCC	406	IHC	Santa Cruz	NA	>25%	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	OS RFS	8
Cui^Citation20	2012	China	HCC	52	IHC	Beijing Boaosen	NA	>10%	35/17 13/21	26/15 9/2	NA	NA	26/9 9/8	14/15 21/2	NA	17/2 18/15	30/4 8/10	NA	NA	6
Xia et al^Citation21	2012	China	HCC	306	IHC	Santa Cruz	NA	>25%	201/105 62/244	158/86 43/19	NA	174/80 27/24	158/82 43/23	102/77 99/28	124/71 76/34	115/45 86/60	68/16 133/89	136/87 65/18	OS RFS	9
Chen^Citation22	2014	China	HCC	92	IHC	ABGENT	1:300	>25%	45/47 8/59	37/39 8/8	38/44 7/3	25/24 20/23	16/19 23/25	27/26 24/15	NA	7/0 38/47	18/4 27/43	33/39 12/8	OS DFS	7
Shi^Citation15	2015	China	HCC	173	IHC	ABGENT	1:300	>25%	NA	99/48 17/9	102/47 14/10	61/27 55/30	71/29 35/23	65/36 51/21	NA	13/2 103/55	32/5 84/52	90/49 26/8	OS DFS	9
Meng et al^Citation16	2015	China	HCC	172	IHC	Santa Cruz	NA	NA	NA	68/48 39/17	82/51 25/14	79/54 28/11	52/38 47/19	NA	NA	21/2 86/63	5/5 98/56	77/58 30/7	OS RFS	8
Shi et al^Citation23	2016	China	HCC	210	IHC	ABGENT	1:300	>25%	NA	95/80 18/17	104/75 9/22	60/47 53/49	47/34 56/58	NA	NA	14/4 99/93	39/12 74/85	72/80 41/17	OS DFS	9
Egawa et al^Citation13	2017	Japan	HCC	79	RT-PCR	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	OS DFS	8
Shang et al^Citation24	2017	China	HCC	100	IHC	ProteinTech Group	NA	>25%	NA	45/29 19/7	16/9 48/27	40/21 24/15	NA	18/17 46/19	NA	22/6 42/30	12/4 52/32	11/20 53/16	NA	7
Yu et al^Citation25	2017	China	HCC	46	IHC	Santa Cruz	1:100	>25%	NA	28/9 7/2	30/8 5/3	NA	19/3 16/8	NA	24/8 11/3	4/0 31/11	13/2 24/11	NA	NA	6

Abbreviations: UICC, Union for International Cancer Control; NOS, The Newcastle-Ottawa Scale; IHC, immunohistochemistry; NA, not applicable; OS, overall survival; RFS, recurrence-free survival; DFS, disease-free survival.

FornerALlovetJMBruixJHepatocellular carcinomaLancet20123799821245125522353262

 PubMed Web of Science ®Google Scholar

LinMGuoLMLiuHNuclear accumulation of glioma-associated oncogene 2 protein and enhanced expression of forkhead-box transcription factor M1 protein in human hepatocellular carcinomaHistol Histopathol201025101269127520712011

 PubMed Web of Science ®Google Scholar

ZhangLThe expression and clinical significance of FoxMB1 in hepatocellular carcinoma and the relationship with MTA1 and MMP-2ThesisGuangxi Medical University (In Chinese)2010

 Google Scholar

SunHCLiMLuJLOverexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinomaOncology Rep201125615331539

 Web of Science ®Google Scholar

SunHTengMLiuJFOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteriaCancer Lett2011306221422221482449

 PubMed Web of Science ®Google Scholar

Upregulated FoxMo PM1 expression induced by TNF-α/ROS/HIF-1α pathway promotes HCC proliferation and resistance to apoptosisThesis Fourth Military Medical University2012 Available from: http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CDFD&dbname=CDFD1214&filename=1012038774.nh&v=MTUwNzRFYlBJUjhlWDFMdXhZ-UzdEaDFUM3FUcldNMUZyQ1VSTEtmWXVkb0Z5cmhVTDNPVkYyNkhMTzdGdGJMcTU=

 Google Scholar

CuiKThe expression and significance of FoxM1 and MMP-2 in hepatocellular carcinomaThesisHuazhong University of Science and Technology2012

 Google Scholar

XiaLHuangWTianDUpregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinomaJ Hepatol201257360061222613004

 PubMed Web of Science ®Google Scholar

ChenDExpression of Gli2 and FoxM1 in hepatocellular carcinoma and their relationship with clinical prognosisThesis NanChang University2014

 Google Scholar

ShiCThe molecular mechanisms by which Gli2 promotes hepatocellular cancer cell proliferation through induction of FoxM1/KIF20A expressionThesis NanChang University2015

 Google Scholar

MengFDWeiJ-CQuKFoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinomaWorld J Gastroenterol201521119621325574092

 PubMed Web of Science ®Google Scholar

ShiCHuangDLuNAberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosisOncotarget2016718262062621927036048

 PubMedGoogle Scholar

EgawaMYoshidaYOguraSIncreased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinomaHepatol Res201747111196120528002884

 PubMed Web of Science ®Google Scholar

ShangRPuMLiYWangDFOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expressionOncology Rep201737422612269

 Web of Science ®Google Scholar

YuCPYuSShiLFoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1Mol Med Rep20171645181518828849004

 PubMed Web of Science ®Google Scholar